Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson's Disease in Canada
Shots:
- The launch of Onstryv follows its Health Canada approval received on Jan 15- 2019 as an add-on therapy to a levodopa regimen indicated to treat signs and symptoms of idiopathic Parkinson’s disease in patients with off episodes
- Valeo Pharma has exclusive rights for Onstryv and is responsible for all regulatory- quality- commercialization and distribution activities in Canada under an agreement with Zambon signed on Apr’2017
- Onstryv (marketed as Xadago in ROW) is an oral- selective & reversible MAO-B-inhibitor- available in Canadian pharmacies as 50mg & 100mg tablets
Click here to read full press release/ article | Ref: Business Wire | Image: LinkedIn
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com